Arcutis Biotherapeutics granted 37,000 restricted stock units to new employees

From GlobeNewswire: 2024-09-05 16:00:00

Arcutis Biotherapeutics, Inc. granted 37,000 restricted stock units to new employees on September 3, 2024. These awards were approved by the Compensation Committee and vest over four years. The stock units were granted as an inducement for the new employees. Arcutis is focused on developing innovations in immuno-dermatology and has a growing portfolio of FDA-approved products. The company is committed to addressing the urgent needs of individuals with immune-mediated dermatological conditions. For more information, visit www.arcutis.com.

Disclaimer: Forward-looking statements in this press release caution that risks and uncertainties may impact actual results. The company advises not to rely solely on these statements and encourages a review of the “Risk Factors” section in their Form 10-K filed with the SEC. Arcutis undertakes no obligation to update forward-looking statements. For media inquiries, contact Amanda Sheldon at [email protected]. For investor relations, contact Latha Vairavan at [email protected].



Read more at GlobeNewswire: Arcutis Biotherapeutics Reports Inducement Grants Under